<DOC>
	<DOCNO>NCT02429895</DOCNO>
	<brief_summary>A Phase 2 , Multicenter , Open-Label Extension ( OLE ) Study ABT-122 Active Psoriatic Arthritis Subjects Who Have Completed Preceding Study M14-197 Phase 2 Randomized Controlled Trial ( RCT ) .</brief_summary>
	<brief_title>A Phase 2 , Multicenter Open-Label Extension ( OLE ) Study With ABT-122 Active Psoriatic Arthritis Subjects Who Have Completed Preceding Study M14-197</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<criteria>1 . Subjects complete precede Study M14197 ( ABT122 ) RCT study develop discontinuation criterion Study M14197 . 2 . If female , subject must meet one follow criterion : Postmenopausal ( define menses least 1 year ) . Surgically sterile ( bilateral oophorectomy hysterectomy ) If subject meet one two category , subject must use one follow method birth control , time first dose study drug 150 day last dose study drug : Combined ( estrogen progestogen contain ) hormonal contraception associate inhibition ovulation start least 2 month prior first dose study drug : oral , intravaginal transdermal Progestogenonly hormonal contraception associate inhibition ovulation start least two month prior randomization : oral , injectable , implantable Intrauterine device ( IUD ) Intrauterine hormonereleasing system ( IUS ) Bilateral tubal occlusion/ligation Be vasectomize partner ( procedure least 6 month earlier , vasectomized male partner sole partner ) Sexual abstinence ( refrain heterosexual intercourse entire study period ) 3 . If male , subject must surgically sterile ( vasectomy 6 month prior Screening ) must practice least 1 follow method birth control time first dose study drug 150 day post last dose study drug : Subject use condom female partner ( ) use intrauterine device ( IUD ) ; Subject use condom female partner ( ) use hormonal contraceptive ( oral , vaginal , parenteral transdermal ) ; Subject use condom female partner ( ) use doublebarrier method ( contraceptive sponge ; diaphragm vaginal ring spermicidal jelly , cream , spermicide ) ; Total abstinence sexual intercourse prefer lifestyle subject ; periodic abstinence acceptable . Subject must also agree donate sperm start first day study drug administration 150 day last dose study drug . 4 . Subjects must voluntarily sign date inform consent , approve Independent Ethics Committee ( IEC ) /Institutional Review Board ( IRB ) , prior initiation studyspecific procedure . 5 . Subject judge good health determine Investigator . 1 . Pregnant breastfeeding plan become pregnant study participation . 2 . Ongoing infection Day 1 ( Week 0 ) NOT successfully treat within 14 day . 3 . Anticipated requirement receipt live vaccine study participation include 120 day last dose study drug . 4 . Current enrollment another investigational study ; exception Study M14197 , require . 5 . Consideration Investigator , reason , subject unsuitable candidate continue receive ABT122 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Methotrexate</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
</DOC>